Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
Question
Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
Direct answer
Statistically significant UACR reductions derisk inaxaplin pivotal Phase III AMPLITUDE outcomes, improving VRTX medium-term non-cystic fibrosis franchise valuations. — bullish pressure on VRTX via clinical pipeline expansion into nephrology beyond core cystic fibrosis portfolio.
- Original publisher
- Market Ontology
- Evidence through
- 2026-09-24
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial”, revision 1, evidence through 2026-09-24. https://marketontology.com/catalysts/2026-09-24/vertex-inaxaplin-phase-iib-cuts-proteinuria-in-kidney-disease-trial-07180c
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| VRTX | ▲Bull | 1–5 days | clinical pipeline expansion into nephrology beyond core cystic fibrosis portfolio | 50 |
Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease Trial
Statistically significant UACR reductions derisk inaxaplin pivotal Phase III AMPLITUDE outcomes, improving VRTX medium-term non-cystic fibrosis franchise valuations. — bullish pressure on VRTX via clinical pipeline expansion into nephrology beyond core cystic fibrosis portfolio.
Vertex posted Phase IIb AMPLIFIED study showing 42.7% UACR reduction and completed AMPLITUDE pivotal study enrollment.
- SourceVertex posted Phase IIb AMPLIFIED study showing 42.7% UACR reduction and completed AMPLITUDE pivotal study enrollment.
- TransmissionStatistically significant UACR reductions derisk inaxaplin pivotal Phase III AMPLITUDE outcomes, improving VRTX medium-term non-cystic fibrosis franchise valuations.
- SummaryVertex reported a 42.7% UACR reduction with inaxaplin in APOL1-mediated kidney disease. In patients with AMKD and concurrent type II diabetes, UACR declined 17.3%. Enrollment for the pivotal Phase II/III AMPLITUDE trial has completed.
- VRTXDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- VRTX closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- VRTX price vs. pre-event level
- VRTX volume vs. 20-day average
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| VRTX | Bullishdisagreed | 522.38 2026-09-24 | +0.73% | -2.99% | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Vertex Posts Positive Phase II Data on Kidney Disease Drug · POLYGON NEWS · 2026-09-23
Related catalysts
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
- 2026-09-24Vertex Inaxaplin Phase IIb Cuts Proteinuria in Kidney Disease TrialVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-24Vertex Reports Positive Phase IIb Kidney Disease Data for InaxaplinVRTX-2.99%
- 2026-09-24Vertex reports positive Phase IIb inaxaplin results for kidney diseaseVRTX-2.99%
- 2026-09-24Vertex Reports Phase IIb Data for Inaxaplin with 42.7% Proteinuria Drop in AMKDVRTX-2.99%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.